Chronic Venous Occlusions Treatment Market Size (2024 - 2029)

Chronic Venous Occlusions Treatment Market Analysis

The Chronic Venous Occlusions Treatment Market size is estimated at USD 7.92 billion in 2024, and is expected to reach USD 10.79 billion by 2029, growing at a CAGR of 6.38% during the forecast period (2024-2029).

Chronic venous occlusion treatment is used to treat chronic venous diseases. Venous occlusion is when veins are blocked, narrowed, or compressed by nearby structures such as clots, muscles, arteries, or other veins. This can result in blood pooling and flowing backward, causing pain and swelling in the area.

The high prevalence of venous occlusion diseases globally drives the market's growth. For instance, a study published in the International Wound Journal in May 2024 revealed that the mean prevalence of chronic venous diseases was 58.4%, and the prevalence of varicose veins was 22.1%. Such a high prevalence of disease at the global level propels the market's growth.

Major market players are increasingly making strategic moves, such as acquisitions, to bolster their product portfolios, particularly in minimally invasive devices for vascular disease treatment.

For instance, in May 2024, Siemens Healthineers, through its subsidiary Varian, finalized the acquisition of Innova Vascular. Innova Vascular, a prominent player in the medical device industry, specializes in cutting-edge, minimally invasive devices tailored for vascular disease treatment. The flagship product, the Laguna Thrombectomy System, is lauded for its exceptional flexibility, trackability, and diverse range of sizes.

These attributes enable healthcare providers to address venous thromboembolism across patient profiles and clot variations effectively. With this acquisition, Siemens Healthineers has significantly bolstered its offerings for blood clot treatments, setting the stage for substantial growth in this market during the forecast period.

Additionally, pharmaceutical companies are increasingly spearheading initiatives to raise awareness about treating venous insufficiency to propel market growth during the forecast period. For example, in July 2023, LES LABORATOIRES SERVIER rolled out a comprehensive campaign dedicated to venous disease awareness. By closely collaborating with healthcare professionals and patients, the company aims to deepen the understanding of venous insufficiency and enhance symptom management. These concerted efforts from pharmaceutical entities are poised to drive market growth in the coming years.

Thus, owing to the abovementioned factors, such as the high prevalence of venous diseases, increasing awareness of venous diseases, and the launch of new products, the growth of the market is the majority driving it. However, the cost compilations and risk associated with treatment may hinder the growth of the market.

Chronic Venous Occlusions Treatment Industry Segmentation

As per the scope of the report, venous occlusion is a condition in which a vein becomes narrowed, blocked, or compressed by nearby structures such as clots, muscles, arteries, or other veins, which results in blood pooling and flowing backward, causing swelling and pain in the area. The introduction of new technology to treat venous occlusion is expected to emerge, and the market is likely to witness more vertical integration and joint ventures during the forecast period.

The chronic venous occlusion treatment market is segmented by treatment type, product type, and geography. The market is segmented by treatment type into chronic deep vein thrombosis, varicose veins, deep vein insufficiency, and other treatment types. By product type, the market is subsegmented into devices and therapeutics. By geography, the market is sub-segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (in USD) for the above segments. The report also covers the estimated market sizes and trends for 17 countries across the major regions globally.